Aptevo Therapeutics (APVO) Stock Price, News & Analysis

Company Overview

Aptevo Therapeutics Inc. is a biotechnology company developing targeted immunotherapies for cancer and other serious diseases. The company is headquartered in Seattle, Washington, and was established in 2016 as a spin-off from Emergent BioSolutions.

Aptevo’s research is based primarily on its ADAPTIR and ADAPTIR-FLEX antibody platforms, which are designed to create bispecific immune-cell engagers. These therapies are intended to connect immune cells with cancer cells or activate immune pathways to produce a targeted response. The company’s development programs have included APVO436, an investigational therapy directed at CD123 and CD3 for certain blood cancers, as well as additional candidates targeting solid tumors and hematologic malignancies.

Aptevo previously marketed IXINITY, a recombinant factor IX therapy for the treatment and prevention of bleeding in people with hemophilia B. The company sold the product to Medexus Pharmaceuticals in 2022 and has since focused primarily on its immunotherapy pipeline. Its clinical development and collaboration activities may involve patients, research institutions, and partners in the United States and other markets. Marvin White has served as the company’s president and chief executive officer.

Key Stats

• Today's Range: $1.31 to $1.39
• 50-Day Range: $1.28 to $2.68
• 52-Week Range: $1.25 to $28.44
• Volume: 17,524 shs
• Average Volume: 45,353 shs
• Market Capitalization: $2.43 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: Sell

Aptevo Therapeutics Stock Analysis - MarketRank™

Aptevo Therapeutics scored higher than 25% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 0.7 / 5
• Analyst Rating: Sell

Consensus Rating

Aptevo Therapeutics has received a consensus rating of Sell. The company's average rating score is 1.00, and is based on no strong buy ratings, no buy ratings, no hold ratings, and 1 sell rating.

Amount of Analyst Coverage

Aptevo Therapeutics has only been the subject of 1 research reports in the past 90 days.

Earnings and Valuation

• Score: 1.3 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Aptevo Therapeutics are expected to grow in the coming year, from ($17.04) to ($6.59) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Aptevo Therapeutics is -0.03, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Aptevo Therapeutics is -0.03, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Aptevo Therapeutics has a P/B Ratio of 0.08. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

Short Interest

• Score: 4.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

5.35% of the float of Aptevo Therapeutics has been sold short.

Short Interest Ratio / Days to Cover

Aptevo Therapeutics has a short interest ratio ("days to cover") of 1.93, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Aptevo Therapeutics has recently decreased by 19.20%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Aptevo Therapeutics does not currently pay a dividend.

Dividend Growth

Aptevo Therapeutics does not have a long track record of dividend growth.

News and Social Media

• Score: 3.9 / 5
• News Sentiment: 1.18

News Sentiment

Aptevo Therapeutics has a news sentiment score of 1.18. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.67 average news sentiment score of Healthcare companies.

News Coverage This Week

MarketBeat has tracked 4 news articles for Aptevo Therapeutics this week, compared to 2 articles on an average week.

MarketBeat Follows

2 people have added Aptevo Therapeutics to their MarketBeat watchlist in the last 30 days.

Company Ownership

• Score: 0.1 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Aptevo Therapeutics insiders have not sold or bought any company stock.

Percentage Held by Insiders

0.37% of the stock of Aptevo Therapeutics is held by insiders.

Percentage Held by Institutions

8.06% of the stock of Aptevo Therapeutics is held by institutions.

Company Calendar

• Last Earnings: 8/14/2026
• Today: 11/01/2026
• Next Earnings (Estimated): 11/05/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Healthcare
• Industry: Biotechnology
• Sub-Industry: Biotechnology
• Current Symbol: NASDAQ:APVO
• CIK: 1671584
• Web: www.aptevotherapeutics.com
• Phone: (206) 838-0500
• Fax: 206-838-0503
• Employees: 33
• Year Founded: 2016

Profitability

• EPS (Trailing Twelve Months): ($51.83)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$25.97 million
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -201.49%
• Return on Assets: -119.21%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 2.08
• Quick Ratio: 2.08

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $17.42 per share
• Price / Book: 0.08

Miscellaneous

• Outstanding Shares: 1,810,000
• Free Float: 1,803,000
• Market Cap: $2.43 million
• Optionable: Not Optionable
• Beta: 1.67